Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study aims to predict who will benefit from liver cancer immunotherapy

NCT ID NCT07623265

First seen Jun 12, 2026 · Last updated Jun 18, 2026 · Updated 1 time

Summary

This study looks at ways to personalize treatment for people with liver cancer (hepatocellular carcinoma). Researchers want to find out which patients are likely to respond to immunotherapy by testing their tumor tissue and blood before treatment starts. The goal is to avoid giving ineffective treatments and their side effects to those who won't benefit. About 300 adults with suspected or confirmed liver cancer will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • AZ Delta

    RECRUITING

    Roeselare, Belgium

    Contact Email: •••••@•••••

    Contact

  • AZ Groeninge

    RECRUITING

    Kortrijk, Belgium

    Contact Email: •••••@•••••

    Contact

  • Jessa ziekenhuis

    RECRUITING

    Hasselt, Belgium

    Contact Email: •••••@•••••

    Contact

  • UZA

    RECRUITING

    Antwerp, Belgium

    Contact Email: •••••@•••••

    Contact

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.